Blood Product Supply
Purpose
Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.
Condition
- COVID-19
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
>_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)
Exclusion Criteria
<18 years of age Prisoners Pregnant women
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Retrospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| future policies on use of blood products from COVID-19-positive donors | Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. |
|
Recruiting Locations
More Details
- NCT ID
- NCT07490314
- Status
- Completed
- Sponsor
- Methodist Health System
Detailed Description
- To identify the circumstances associated with observed delays in receiving blood products to use in emergent cases. - Determine the cost/benefit of moribund patients receiving massive transfusion during the COVID-19 pandemic. - Quantify COVID-19 diagnosis and complications in patients arriving with no indication of disease at index admission as relative to in hospital or blood product exposure.